{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:40:08Z","timestamp":1771479608746,"version":"3.50.1"},"reference-count":26,"publisher":"Japan Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1507\/endocrj.ej20-0836","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T22:12:08Z","timestamp":1620684728000},"page":"1117-1125","source":"Crossref","is-referenced-by-count":6,"title":["Utility of outpatient fractionated radioiodine therapy for Graves disease involving a large goiter measuring more than 100 mL in volume"],"prefix":"10.1507","volume":"68","author":[{"given":"Tetsuya","family":"Mizokami","sequence":"first","affiliation":[{"name":"Tajiri Thyroid Clinic, Kumamoto 862-0950, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Hamada","sequence":"additional","affiliation":[{"name":"Tajiri Thyroid Clinic, Kumamoto 862-0950, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsushi","family":"Maruta","sequence":"additional","affiliation":[{"name":"Tajiri Thyroid Clinic, Kumamoto 862-0950, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiichiro","family":"Higashi","sequence":"additional","affiliation":[{"name":"Tajiri Thyroid Clinic, Kumamoto 862-0950, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Tajiri","sequence":"additional","affiliation":[{"name":"Tajiri Thyroid Clinic, Kumamoto 862-0950, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1 Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, et al. (2016) 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26: 1343\u20131421.","DOI":"10.1089\/thy.2016.0229"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Kahaly GJ, Bartalena L, Heged\u00fcs L, Leenhardt L, Poppe K, et al. (2018) 2018 European thyroid association guideline for the management of Graves\u2019 hyperthyroidism. Eur Thyroid J 7: 167\u2013186.","DOI":"10.1159\/000490384"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Huysmans DA, Hermus AR, Corstens FH, Barentsz JO, Kloppenborg PW (1994) Large, compressive goiters treated with radioiodine. Ann Intern Med 121: 757\u2013762.","DOI":"10.7326\/0003-4819-121-10-199411150-00005"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Howarth DM, Epstein MT, Thomas PA, Allen LW, Akerman R, et al. (1997) Outpatient management of patients with large multinodular goitres treated with fractionated radioiodine. Eur J Nucl Med 24: 1465\u20131469.","DOI":"10.1007\/s002590050175"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Jeong YA, Yoon JH, Kim HK, Kang H (2018) Graves\u2019 disease patients with large goiters respond best toradioactive iodine doses of at least 15 mCi: a sonographic volumetric study. Int J Thyroidol 11: 137\u2013142.","DOI":"10.11106\/ijt.2018.11.2.137"},{"key":"6","unstructured":"6 Feng HJ, Ouyang W, Hu R, Liu JH, Liu WY (2011) Radioiondine therapy for Graves hyperthyroidism with large goiter: feasibility, efficacy and safety. Nan Fang Yi Ke Da Xue Xue Bao 31: 1464\u20131466. (In Chinese with English abstract)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Tajiri J (2006) Radioactive iodine therapy for goitrous Hashimoto\u2019s thyroiditis. J Clin Endocrinol Metab 91: 4497\u20134500.","DOI":"10.1210\/jc.2006-1163"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Mizokami T, Hamada K, Maruta T, Higashi K, Tajiri J (2016) Painful radiation thyroiditis after <sup>131<\/sup>I Therapy for Graves\u2019 hyperthyroidism: clinical features and ultrasonographic findings in five cases. Eur Thyroid J 5: 201\u2013206.","DOI":"10.1159\/000448398"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kinuya S, Yoneyama T, Michigishi T (2007) Airway complication occurring during radioiodine treatment for Graves\u2019 disease. Ann Nucl Med 21: 367\u2013369.","DOI":"10.1007\/s12149-007-0034-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Watanabe N, Noh JY, Kozaki A, Iwaku K, Sekiya K, et al. (2015) Radioiodine-associated exacerbation of Graves\u2019 orbitopathy in the Japanese population: randomized prospective study. J Clin Endocrinol Metab 100: 2700\u20132708.","DOI":"10.1210\/jc.2014-4542"},{"key":"11","unstructured":"11 Hollenberg A, Wiersinga WM (2020) Hyperthyroid disorders. In: Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ (ed) Williams Textbook of Endocrinology (14th). Elsevier, Philadelphia, USA: 364\u2013403."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Kitahara CM, Berrington de Gonzalez A, Bouville A, Brill AB, Doody MM, et al. (2019) Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med 179: 1034\u20131042.","DOI":"10.1001\/jamainternmed.2019.0981"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Taylor PN, Okosieme OE, Chatterjee K, Boelaert K, Executive Committees of the Society for Endocrinology and the British Thyroid Association (2020) Joint statement from the Society for Endocrinology and the British Thyroid Association regarding \u2018Association of Radioactive Iodine Treatment with cancer mortality in patients with hyperthyroidism\u2019 Clin Endocrinol (Oxf) 92: 266\u2013267.","DOI":"10.1111\/cen.14136"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kitahara CM, Preston DL, Sosa JA, Berrington de Gonzalez A (2020) Association of radioactive iodine, antithyroid drug, and surgical treatments with solid cancer mortality in patients with hyperthyroidism. JAMA Netw Open 3: e209660.","DOI":"10.1001\/jamanetworkopen.2020.9660"},{"key":"15","unstructured":"15 Filetti S, Tuttle RM, Sherman SI (2021) Medical management of differentiated epithelial cell thyroid cancer. In: Braverman LE, Cooper DS, Kopp P (ed) Werner and Ingbar\u2019s The Thyroid. A Fundamental and Clinical Text (11th). Wolters Kluwer, Philadelphia, USA: 751\u2013775."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Horvath E, Skoknic V, Majlis S, Tala H, Silva C, et al. (2020) Radioiodine-induced salivary gland damage detected by ultrasonography in patients treated for papillary thyroid cancer: radioactive iodine activity and risk. Thyroid 30: 1646\u20131655.","DOI":"10.1089\/thy.2019.0563"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Bonnema SJ, Heged\u00fcs L (2012) Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 33: 920\u2013980.","DOI":"10.1210\/er.2012-1030"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Sawka AM, Lea J, Alshehri B, Straus S, Tsang RW, Brierley JD, et al. (2008) A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol (Oxf) 68: 610\u2013617.","DOI":"10.1111\/j.1365-2265.2007.03081.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Moura-Neto A, Mosci C, Santos AO, Amorim BJ, de Lima MCL, et al. (2012) Predictive factors of failure in a fixed 15 mCi <sup>131<\/sup>I-iodide therapy for Graves\u2019 disease. Clin Nucl Med 37: 550\u2013554.","DOI":"10.1097\/RLU.0b013e31824851d1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 de Jong JA, Verkooijen HM, Valk GD, Zelissen PM, de Keizer B (2013) High failure rates after <sup>131<\/sup>I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover. Clin Nucl Med 38: 401\u2013406.","DOI":"10.1097\/RLU.0b013e3182817c78"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Walrand S, Hesse M, Jamar F (2015) Statistical and radiobiological analysis of the so-called thyroid stunning. EJNMMI Res 5: 67.","DOI":"10.1186\/s13550-015-0144-9"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Zantut-Wittmann DE, Ramos CD, Santos AO, Lima MMO, Panzan AD, et al. (2005) High pre-therapy [<sup>99m<\/sup>Tc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [<sup>131<\/sup>I]iodide therapy in Graves\u2019 disease. Nucl Med Commun 26: 957\u2013963.","DOI":"10.1097\/01.mnm.0000183795.59097.42"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Alexander EK, Larsen PR (2002) High dose of <sup>131<\/sup>I therapy for the treatment of hyperthyroidism caused by Graves\u2019 disease. J Clin Endocrinol Metab 87: 1073\u20131077.","DOI":"10.1210\/jcem.87.3.8333"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Aung ET, Zammitt NN, Dover AR, Strachan MWJ, Seckl JR, et al. (2019) Predicting outcomes and complications following radioiodine therapy in Graves\u2019 thyrotoxicosis. Clin Endocrinol (Oxf) 90: 192\u2013199.","DOI":"10.1111\/cen.13873"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Ross DS, Daniels GH, De Stefano P, Maloof F, Ridgway EC (1983) Use of adjunctive potassium iodide after radioactive iodine (<sup>131<\/sup>I) treatment of Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab 57: 250\u2013253.","DOI":"10.1210\/jcem-57-2-250"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26 Nishio R, Uchida T, Suzuki L, Onose H, Goto H, et al. (2021) Influence of short-term dietary and therapeutic iodine restriction on the therapeutic effects of radioactive iodine therapy in patients with Graves\u2019 disease. Thyroid 31: 439\u2013445.","DOI":"10.1089\/thy.2020.0126"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/9\/68_EJ20-0836\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T03:34:06Z","timestamp":1633145646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/9\/68_EJ20-0836\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0836","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"EJ20-0836"}}